# First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon <i>EGFR</i> Mutations

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/first-line-osimertinib-for-previously-untreated-patients-with-nsclc-and-uncommon/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yusuke Okuma,Kaoru Kubota,Mototsugu Shimokawa,Kana Hashimoto,Yosuke Kawashima,Tomohiro Sakamoto,Hiroshi Wakui,Shuji Murakami,Kyoichi Okishio,Kenji Hayashihara,Yuichiro Ohe,Tokyo Cooperative Oncology Group (TCOG) |
| Citations | 84 |
| DOI | 10.1001/jamaoncol.2023.5013 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/10666043 |
| OpenAlex ID | https://openalex.org/W4388907858 |
| PMID | 37991747 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Yusuke Okuma](https://scholariq.org/researchers/yusuke-okuma/)

## Paper journal

- [JAMA Oncology](https://scholariq.org/journals/jama-oncology/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Fibroblast Growth Factor Research](https://scholariq.org/topics/fibroblast-growth-factor-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.